A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Trial Profile

A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 02 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top